Researchers at UT Southwestern Medical Heart led a research revealed in JAMA Community Open which discovered that particular chemotherapies are related to an elevated long-term...
The FDA has accepted Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) as the primary and solely subcutaneous, chemo-free therapy for sufferers with EGFR-mutated non-small cell lung most...
Lively Biotech has obtained optimistic suggestions from regulators on a protocol modification to its ongoing proof-of-concept scientific trial evaluating tasquinimod in sufferers with myelofibrosis, a...
This program centered on affected person views and shared decision-making within the context of a number of myeloma, bringing collectively a panel that...
Dr. Vincent Ma mentioned the newest and notable therapy updates for sufferers with high-risk and superior melanoma.Though the 2025 ASCO Annual Assembly didn't...
